At its meeting of 13 February 2023, the Transparency Council adopted Position No. 17/2023 on the evaluation of the medicine Vimetso (vildagliptin + metformin hydrochloride) for the indication for the treatment of type 2 diabetes.
At its meeting of 13 February 2023, the Transparency Council adopted Position No. 17/2023 on the evaluation of the medicine Vimetso (vildagliptin + metformin hydrochloride) for the indication for the treatment of type 2 diabetes.